COVID-19 infection
Conditions
Interventions
Control group:Oral calcic D600 + Saline is injected subcutaneously
Test group:Oral calcic D600 + Disumab was injected subcutaneously
Sponsors
Qilu Hospital of Shandong University (Qingdao)
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Age range from 50 to 90 years; (2) Patients infected with COVID-19 according to nucleic acid results, clinical symptoms, signs and imaging findings; (3) Meet the diagnostic criteria for medium or severe COVID-19: Medium: ? persistent high fever for more than 3 days; ? Cough, shortness of breath but respiratory rate 93% when inhaling air at rest; (4) Imaging shows the characteristic manifestations of COVID-19 pneumonia; Heavy: ? shortness of breath, and respiratory rate >=30 times/min; (2) At rest, oxygen saturation 50% within 24-48 hours; (4) The results of QCT showed that the mean volume bone density of cancellous bone of thoracic vertebra was less than 80mg/cm3 (the diagnostic criteria for osteoporosis). (5) Be able to fully comply with this Agreement mentally and physically, cooperate with the scheduled treatment plan and fill out forms, and cooperate with follow-up visits. (6) After the patient signs the informed consent, it means that the patient has known and agreed to the implementation of the relevant aspects of this study. The above inclusion standards are international general standards to ensure that they are reasonable and feasible.
Exclusion criteria
Exclusion criteria: (1) The patient has a medical condition contrary to the current treatment regimen; (2) Meeting the diagnostic criteria for critical COVID-19: (1) Respiratory failure, requiring mechanical ventilation; ? Shock occurs; ? Patients with other organ failure need ICU care; (3) Previous treatment measures affecting bone metabolism: ? zoledronic acid was used within 12 months; ? Disumab was used within 6 months; ? Other anti-osteoporosis drugs such as calcium, vitamin D, vitamin K2, calcitonin, anti-osteoporosis Chinese medicine were used within 3 months; (4) severe obesity and history of drug abuse; (5) Pregnancy or pregnancy plan during the study; (6) Participating in other studies that may affect the results of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone density; | — |
Countries
China
Contacts
Public ContactYingjun Guo
Qilu Hospital of Shandong University (Qingdao)
Outcome results
None listed